September 29, 2016 7:11am

 

Is a zero sum game …

The game is often used as a choosing method in a way similar to, share dipping, short tipping and buying based on throwing dice

 

I answer one question; in which company should investors put, keep and commit their money!

 

Where is “our” universe going today?  Astute investors subscribe, you should too! 

 

I say what others won't, so you can do what others can't!

Read me or discount me, I make investors’ money!

 


 

How does the old saying go? It's easier to ask for forgiveness than ask for permission. Maybe it's the other way around. Whatever the case, to the extent I need to, I'm NOT going to ask for forgiveness for what I say – someone NEEDS to speak up and out!

 

 

Indexes and ETFs: The IWM, XLV, IBB and XBI are NOT indicating

I am taking a PAUSE as to prognostication, let's see how the sector ... floats as the month and quarter ends

 

Dow futures are DOWN -0.02% and NASDAQ futures are DOWN -0.09%

 

 

U.S. stock-index futures signaled a flat start to trade on Thursday, as European and some Asian shares rose after an accord was struck among OPEC members was struck.

European stocks were higher in morning trade as investor sentiment was buoyed by a surge in the oil price after major oil producers agreed to cut production levels.

Asian markets closed higher after an oil-price rally amid reports of potential production cuts, but India's shares dropped after reports that the Indian army conducted strikes against militants in the disputed region of Kashmir.

 

Data docket: there will be the third estimate of U.S. second-quarter gross domestic product (GDP); international goods trade figures for August and pending home sales for the month. There will also be U.S. weekly initial jobless claims.

  • U.S. Federal Reserve Chair Janet Yellen will speak in Kansas City at 4 p.m. ET at a forum on banking and the economy. Before that, Fed Governor Jerome Powell will speak in St. Louis about trends in community bank performance.

 

 

The stem, cell, gene and regenerative therapy (SCG&RT) sector closed NEGATIVE on Wednesday, POSITIVE on Tuesday, NEGATIVE on Monday, POSITIVE on Friday and last Thursday.

The SCG&RT sector’s record after the last 5 days (of 43 covered companies):

  • Wednesday closed NEGATIVE with 27 decliners, 13 advancers and 3 flats;
  • Tuesday closed POSITIVE with 15 decliners, 27 advancers and 1 flat;
  • Monday closed NEGATIVE with 33 decliners, 9 advancers and 1 flat;
  • Friday closed POSITIVE with 20 decliners, 22 advancers and 1 flat;
  • Last Thursday closed POSITIVE with 16 decliners, 23 advancers and 4 flats;

 

 

Remembering Wednesday’s closing post, “Share and pricing turnover is a factor, how many time does the volume trend in relation to its pricing or the reverse?  Technicals and fundamentals matter yet they seem over-ridden on multiple occasions. Relative strength is also not always a short-term indicator. For short-term overbought, we also must consider the day moving averages.

Reiterating, don’t wish for the quarter to be over so quickly because, even though October, on average, is not as terrible a month as September, it has been even more volatile in the past — the most volatile of the entire calendar.

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? 

Watch list:

  • The iShares Nasdaq Biotechnology (IBB) closed Wednesday down -0.81% and is NOT indicating in Thursday’s pre-market;
  • The SPDR S&P Biotech ETF (XBI) closed Wednesday down -1.38% and is NOT indicating in Thursday pre-market;
  • The Health Care Select Sector SPDR ETF (XLV) closed down -0.11% Wednesday and is NOT indicating in Thursday’s pre-market;
  • The iShares Russell 2000 (IWM) closed up +0.77% on Wednesday and is NOT indicating in Thursday’s pre-market.

 

Companies in my headlights:

  • I am taking a pause in a daily forecast

 

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.